For instance, the Phase Ib TATTON study of osimertinib combined with durvalumab suggested the possibility of an increased incidence of interstitial lung disease.[21] In another phase I study of 56 patients receiving durvalumab in combination with gefitinib, the incidence of hepatic AEs was significantly higher than previously reported with either gefitinib or durvalumab monotherapy.[22] Grade 3/4 adverse events—including ALT elevation (7%), pyrexia (7%), and rash (7%)—occurred in 39% of patients in the phase Ib study of atezolizumab plus erlotinib. Here, GPT is linked to interstitial lung disease.